Article Text

FRI0214 Six-Year Retention Rate of Abatacept in Rheumatoid Arthritis: A Multicentric Retrospective Analysis
  1. E.G. Favalli1,
  2. C. Botsios2,
  3. C. Bazzani3,
  4. B. Raffainer4,
  5. G. Ciancio5,
  6. A. Giollo6,
  7. A. Marchesoni1,
  8. R. Gorla3,
  9. C. Caimmi6,
  10. A. Becciolini1,
  11. C. Crotti7,
  12. S. Piantoni3,
  13. M. Biggioggero7,
  14. A. Carletto6
  1. 1Department of Rheumatology, Gaetano Pini Institute, Milano
  2. 2Rheumatology Unit, Department of Medicine, University of Padova, Padova
  3. 3Rheumatology Unit and Chair, Spedali Civili and University of Brescia, Brescia
  4. 4Internal Medicine Division, Azienda Sanitaria dell'Alto Adige, Bolzano
  5. 5Rheumatology Unit, Department of Medical Sciences, Azienda Ospedaliera-Universitaria Sant'Anna, Ferrara
  6. 6Rheumatology Unit, Department of Medicine, University of Verona, Verona
  7. 7Department of Clinical Sciences and Community Health, Division of Rheumatology, University of Milan and Gaetano Pini Institute, Milano, Italy


Background Abatacept (ABT) short-term efficacy and safety profile in the treatment of rheumatoid arthritis (RA) is well established and supported by randomised controlled trials. However, data on ABT long-term effects are still lacking and reported drug survival analyses are often limited to no more than 2-year follow-up.

Objectives The aim of the study is to evaluate in a real-life scenario the overall 6-year retention rate of ABT in the treatment of RA and to compare its survival rate as first or second line biotherapy.

Methods Data were retrospectively extracted from six local registries including all RA patients treated with ABT between January 2008 and April 2015. The analysis was limited to patients treated with ABT as first or second line biologic agent. The 6-year retention rate was calculated by Kaplan-Meier method and the comparative risk for discontinuation between the two lines of treatment was compared by a stratified log-rank test.

Results 236 RA patients (78.5% female, mean age [± standard deviation, SD] 57.6 [±12.7] years, mean disease duration 14.3 [±13.4] years, positive rheumatoid factor 82.2%, positive anti-citrullinated peptide antibodies 71.1%, mean DAS28 5.19 [±1.2]) were retrospectively enrolled. 83 patients were treated with ABT as first-line biotherapy, whereas 153 were second-line users. The overall retention rate was 63.7% at 3 years and 61.8% at 6 years. The 6-year retention rate was significantly higher in the first-line compared with the second-line therapy group (68% and 61.8%, respectively; p=0.04). Overall, ABT was discontinued in 69 (29.2%) patients. Twenty-one (8.9%) patients (4 first-line and 17 second-line users, p=0.15) withdrew ABT because of adverse events, whereas 41 (17.4%) patients (10 first-line and 31 second-line users, p=0.1508) stopped the therapy because of primary or secondary inefficacy. Seven (2.7%) patients discontinued ABT because of other reasons (i.e. lost at follow-up, pregnancy and remission) and were excluded from the retention analysis.

Conclusions In our multicentric experience the 6-year retention rate of both first and second line ABT was about 60%. Used as first line ABT showed a significantly higher survival on treatment compared with the second line. Moreover, ABT demonstrated an overall favourable safety profile, with a very low occurrence of adverse events leading to discontinuation.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.